Cargando…

Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea

A 22-year-old male patient was diagnosed with autosomal dominant polycystic kidney disease (ADPKD). He received conservative treatment with an angiotensin-converting enzyme inhibitor. Two years later, oral therapy, consisting of 60 mg tolvaptan per day, was initiated. Compared with height-adjusted t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ha Yeon, Lee, Seung Jin, Kim, Byung Ki, Kim, Minah, Bae, Eun Hui, Ma, Seong Kwon, Kim, Soo Wan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Electrolyte Metabolism 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414314/
https://www.ncbi.nlm.nih.gov/pubmed/30899311
http://dx.doi.org/10.5049/EBP.2018.16.2.23
_version_ 1783402955296210944
author Kim, Ha Yeon
Lee, Seung Jin
Kim, Byung Ki
Kim, Minah
Bae, Eun Hui
Ma, Seong Kwon
Kim, Soo Wan
author_facet Kim, Ha Yeon
Lee, Seung Jin
Kim, Byung Ki
Kim, Minah
Bae, Eun Hui
Ma, Seong Kwon
Kim, Soo Wan
author_sort Kim, Ha Yeon
collection PubMed
description A 22-year-old male patient was diagnosed with autosomal dominant polycystic kidney disease (ADPKD). He received conservative treatment with an angiotensin-converting enzyme inhibitor. Two years later, oral therapy, consisting of 60 mg tolvaptan per day, was initiated. Compared with height-adjusted total kidney volume, the rate of kidney growth reduced significantly from 7.33% to 0.66% annually, since commencement of the tolvaptan therapy. The liver enzyme profile and serum sodium level and osmolality were constantly within normal ranges. In Korea, this is the first reported case of a patient with ADPKD who received tolvaptan treatment for more than 1 year. This case demonstrates that long-term tolvaptan treatment appears to be safe, well tolerated, and effective for ADPKD.
format Online
Article
Text
id pubmed-6414314
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Korean Society of Electrolyte Metabolism
record_format MEDLINE/PubMed
spelling pubmed-64143142019-03-21 Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea Kim, Ha Yeon Lee, Seung Jin Kim, Byung Ki Kim, Minah Bae, Eun Hui Ma, Seong Kwon Kim, Soo Wan Electrolyte Blood Press Case Report A 22-year-old male patient was diagnosed with autosomal dominant polycystic kidney disease (ADPKD). He received conservative treatment with an angiotensin-converting enzyme inhibitor. Two years later, oral therapy, consisting of 60 mg tolvaptan per day, was initiated. Compared with height-adjusted total kidney volume, the rate of kidney growth reduced significantly from 7.33% to 0.66% annually, since commencement of the tolvaptan therapy. The liver enzyme profile and serum sodium level and osmolality were constantly within normal ranges. In Korea, this is the first reported case of a patient with ADPKD who received tolvaptan treatment for more than 1 year. This case demonstrates that long-term tolvaptan treatment appears to be safe, well tolerated, and effective for ADPKD. The Korean Society of Electrolyte Metabolism 2018-12 2018-12-31 /pmc/articles/PMC6414314/ /pubmed/30899311 http://dx.doi.org/10.5049/EBP.2018.16.2.23 Text en Copyright © 2018 The Korean Society of Electrolyte Metabolism http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kim, Ha Yeon
Lee, Seung Jin
Kim, Byung Ki
Kim, Minah
Bae, Eun Hui
Ma, Seong Kwon
Kim, Soo Wan
Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
title Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
title_full Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
title_fullStr Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
title_full_unstemmed Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
title_short Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
title_sort long-term tolvaptan treatment of autosomal dominant polycystic kidney disease in korea
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414314/
https://www.ncbi.nlm.nih.gov/pubmed/30899311
http://dx.doi.org/10.5049/EBP.2018.16.2.23
work_keys_str_mv AT kimhayeon longtermtolvaptantreatmentofautosomaldominantpolycystickidneydiseaseinkorea
AT leeseungjin longtermtolvaptantreatmentofautosomaldominantpolycystickidneydiseaseinkorea
AT kimbyungki longtermtolvaptantreatmentofautosomaldominantpolycystickidneydiseaseinkorea
AT kimminah longtermtolvaptantreatmentofautosomaldominantpolycystickidneydiseaseinkorea
AT baeeunhui longtermtolvaptantreatmentofautosomaldominantpolycystickidneydiseaseinkorea
AT maseongkwon longtermtolvaptantreatmentofautosomaldominantpolycystickidneydiseaseinkorea
AT kimsoowan longtermtolvaptantreatmentofautosomaldominantpolycystickidneydiseaseinkorea